{"id":7171,"date":"2026-02-19T10:39:00","date_gmt":"2026-02-19T09:39:00","guid":{"rendered":"https:\/\/www.ffrdiabete.org\/?p=7171"},"modified":"2026-02-19T14:29:44","modified_gmt":"2026-02-19T13:29:44","slug":"a-promising-avenue-for-the-treatment-of-mash-3","status":"publish","type":"post","link":"https:\/\/www.ffrdiabete.org\/en\/a-promising-avenue-for-the-treatment-of-mash-3\/","title":{"rendered":"The FFRD 2026 press conference lives on… Watch the replay!"},"content":{"rendered":"

[vc_row][vc_column][vc_column_text css=””]Take a look back at the FFRD press conference<\/strong> held on past January 20.<\/span><\/p>\n

\n

It’s an opportunity to look back at the highlights of this event: FFRD updates, the FFRD 2026 Call for Proposals<\/a><\/strong>, the FFRD symposium on epigenetic<\/strong> at the SFD congress in Lyon<\/a><\/strong>, international communications and publications, the two 2025 FFRD awardees<\/a><\/strong>, the SFDT1<\/strong> cohort supported by the FFRD – which has just launched DIABANDCO<\/a><\/strong>, a data valorization company – and finally the brand-new national study <\/strong> \u00e0 la promoted by the FFRD : PR\u00caT1D<\/a><\/strong>!<\/span><\/p>\n

 <\/p>\n<\/div>\n

<\/div>\n

WATCH THE REPLAY<\/strong><\/a><\/h4>\n

 <\/p>\n

\"\"<\/a><\/p>\n

 <\/p>\n

The COMPLETE PRESS KIT<\/strong><\/a> is available online to view at your convenience:<\/p>\n